With our mock-up profile, we note: (1) two CRC cell lines with identical case profile matching, except for ARID1A mutation; (2) increased relative cetuximab sensitivity in the case profile matched cell lines without ARID1A mutation; and (3) among ATR signaling pathway compounds, a reversal in the designation as the least and most sensitive, depending on ARID1A mutation profile inclusion (Figure S5). This evidence concerns the gene ARID1A and colorectal carcinoma.